Mauna Kea touts Cellvizio pancreatic cyst diagnosis data

Mauna Kea (ENT:MKEA) today touted the results from a recently published study of its Cellvizio system which supported the use of the device in diagnosing pancreatic cysts. The Cellvizio device is designed for use in a variety of surgical procedures, providing real time visualization at the microscopic level, Mauna Kea said. Results from the study were published in the World Journal of Gastroenterology, the French company said. In the study, researchers evaluated in vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions, Mauna Kea reported. The researchers concluded that in vivo nCLE patterns were reproducible in ex vivo pCLE for all major neoplastic pancreatic cysts. “This new peer reviewed study led by Dr. Krishna provides further validation of the application of Cellvizio needle-based CLE in the diagnosis of pancreatic cysts. There is a significant opportunity for clinicians to use optical biopsy with Cellvizio in the often-challenging task of diagnosing pancreatic cysts, allowing them to make faster diagnoses and better treatment decisions to achieve better outcomes for their patients,” CEO Sacha Loiseau said in a prepared release. In May, Mauna Kea touted data from a study examining the use of its Cellvizio platform in assessing acute lung rejection following transplant. Results from follow-up exams of 24 lung transplant patients were used in the study, with CLE video-imaging obtained prior to tissue sampling, Mauna Kea said. Endomicroscopy...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Imaging Mauna Kea Technologies Source Type: news

Related Links:

Authors: Rosso L, Zanella A, Righi I, Barilani M, Lazzari L, Scotti E, Gori F, Mendogni P Abstract Lung transplantation is the only therapeutic option for end-stage pulmonary failure. Nevertheless, the shortage of donor pool available for transplantation does not allow to satisfy the requests, thus the mortality on the waiting list remains high. One of the tools to overcome the donor pool shortage is the use of ex-vivo lung perfusion (EVLP) to preserve, evaluate and recondition selected lung grafts not otherwise suitable for transplantation. EVLP is nowadays a clinical reality and have several destinations of use. ...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Authors: Petrella F, Spaggiari L Abstract Lung transplantation remains the definitive curative treatment for end-stage lung disease. However, future applications of tissue bioengineering could overcome the donor organ shortage and the need for immunosuppression. The final goal of lung tissue engineering is to recreate the whole spectrum of specialized lung tissues and thereby provide physiologic functions through bioengineered conducting airways, vasculature and gas exchange tissue. This review focuses on ongoing research in artificial lung development, open questions, achievements to date and how tissue engineeri...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Publication date: September 2018Source: The Annals of Thoracic Surgery, Volume 106, Issue 3Author(s): Marcos N. Samano, Lucas M. Fernandes, Silvia V. Campos, Paulo M. Pêgo-Fernandes
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Publication date: September 2018Source: The Annals of Thoracic Surgery, Volume 106, Issue 3Author(s): Mauricio A. Villavicencio, Andrea L. Axtell, Asishana Osho, Todd Astor, Nathalie Roy, Serguei Melnitchouk, David D’Alessandro, George Tolis, Yuval Raz, Isabel Neuringer, Thoralf M. SundtBackgroundDouble-lung transplantation (DLT) has better long-term outcomes compared with single-lung transplantation (SLT) in pulmonary fibrosis. However, controversy persists about whether older patients or patients with high lung allocation scores would benefit from DLT. Moreover, the degree of pulmonary hypertension in which SLT sho...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
ConclusionsIn the largest analysis of TBI donors and the impact on lung transplantation survival to date, we found similar survival out to 5 years in lung transplant recipients of TBI versus non-TBI donors, alleviating concerns over continued transplantation with this unique donor population.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Publication date: Available online 20 August 2018Source: Indian Heart JournalAuthor(s): Shayan Marsia, Ariba Khan, Maryam Khan, Saba Ahmed, Javeria Hayat, Abdul Mannan Khan Minhas, Samir Mirza, Nisar Asmi, Jonathon ConstantinAbstractDonors after brain dead (DBD) have been the major source of organ donation due to good perfusion of the organs. However, due to the mismatch in demand and supply of the organ donors and recipients, organ donation after circulatory death has increased recently all over the world. Kidneys, liver and lungs are being used for transplantation from Donors after circulatory death (DCDDs). Recently, he...
Source: Indian Heart Journal - Category: Cardiology Source Type: research
Condition:   Lung Transplantation Intervention:   Device: OCS Lung System Sponsors:   TransMedics;   United Network for Organ Sharing Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chronic Lung Allograft Dysfunction (CLAD) is the main cause of morbidity and mortality after the first year following lung transplantation (LTx). Risk factors of CLAD have been extensively studied, but the ass...
Source: BMC Microbiology - Category: Microbiology Authors: Tags: Research article Source Type: research
Histopathology, EarlyView.
Source: Histopathology - Category: Pathology Authors: Source Type: research
Voriconazole exposure and longer duration of voriconazole were found to be significantly associated with increased risk of squamous cell carcinoma. Regular dermatologic surveillance should be considered for the patients taking voriconazole, especially those at high risk of developing squamous cell carcinoma.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
More News: Clinical Trials | France Health | Gastroenterology | Lung Transplant | Pancreas | Study | Transplant Surgery | Transplants